MannKind Corporation

MNKDNASDAQ · Pharmaceutical Preparations

Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

309.9M

on 2026-06-30, from 270.8M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

Newest

No limit

S-3ASR of 2025-02-26. An automatic shelf: the form sets no dollar limit. Sales under the at-the-market programme filed with it are not stated apart. S-3ASR ↗

$200.0M

Cantor Fitzgerald, agreement of 2025-02-26. No at-the-market sales statement read from a 10-Q or 10-K. S-3ASR ↗

Warrants

The 10-Q filed 2026-08-05 is not read yet.

Cash

55.2 quarters

$111.1M on 2026-06-30 ÷ $2.0M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
Date	What	Shares	Price	Gross	Filing
2026-07-23	Private placement incl. 2.41M pre-funded	12,853,470	$3.89	$50.0M	8-K ↗